UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 28, 2022 (
(Exact name of Registrant as Specified in Its Charter)
State of |
||
(State or Other Jurisdiction | (Commission | (IRS Employer |
of Incorporation) | File Number) | Identification No.) |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: +
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) |
Name of each exchange on which registered |
||
* |
* Not for trading; only in connection with the registration of American Depositary Shares.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 9.01
|
Financial Statements and Exhibits
|
|
(d)
|
Exhibits
|
Exhibit
No. |
|
Description
|
|
CHEMOMAB THERAPEUTICS LTD.
|
|
|
|
|
|
|
Date: November 28, 2022
|
By:
|
/s/ Donald Marvin
|
|
|
|
Name: Donald Marvin
|
|
|
|
Title: Executive V.P., Chief Financial Officer
and Chief Operating Officer
|
|
|
|
Very truly yours,
Chemomab Therapeutics, Ltd.
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Dale R. Pfost |
|
|
|
Name: Dale R. Pfost
Title: Chairman & CEO
|
|
|
|
|
|
|
|
ACCEPTED AND AGREED:
Matthew Frankel
|
|
|
|
|
|
|
|
|
|
/s/ Matthew Frankel
|
|
|
|
|
Signature
|
|
|
|
|
|
|
|
|
|
10/11/2022
|
|
|
|
|
Date
|
|
|
|
Document and Entity Information |
Nov. 14, 2022 |
---|---|
Entity Listings [Line Items] | |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | This Form 8-K/A is being filed as an amendment (the “Amendment”) to the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 14, 2022 (“Original Filing”). The sole purpose of this Amendment is to furnish Exhibit 10.1, which was inadvertently omitted in the Original Filing as a result of a clerical error. Other than as described above, this Amendment does not modify or update any disclosures in or exhibits to the Original Filing nor does it reflect any events that may have occurred subsequent to the Original Filing. |
Document Period End Date | Nov. 14, 2022 |
Entity File Number | 001-38807 |
Entity Registrant Name | Chemomab Therapeutics Ltd. |
Entity Central Index Key | 0001534248 |
Entity Incorporation, State or Country Code | L3 |
Entity Tax Identification Number | 00-0000000 |
Entity Address, Address Line One | Kiryat Atidim, Building 7 |
Entity Address, City or Town | Tel Aviv |
Entity Address, Country | IL |
Entity Address, Postal Zip Code | 6158002 |
City Area Code | 972 |
Local Phone Number | 77-331-0156 |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share [Member] | |
Entity Listings [Line Items] | |
Title of 12(b) Security | American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share |
Trading Symbol | CMMB |
Security Exchange Name | NASDAQ |
Ordinary shares, no par value per share [Member] | |
Entity Listings [Line Items] | |
Title of 12(b) Security | Ordinary shares, no par value per share |
Trading Symbol | N/A |
Security Exchange Name | NASDAQ |
;9=F@&PV.8/PX3*(R]$Q(&O[#1-(!?]*@24/DR?$^Q_NUPC
MJE$JQ0EB%MR/H)?-XIJY'<6ZLPH!TEX&P!Y,\N !_QD;@]
M42K%I^!2HD H,,#RX?--6\MURGT5F'5=RSKJWZY!^I1E18%5N>/-0>D_4KF:
MZ-+UOQ2^/11D<[O\/0($(DYE)NVRMO%':JKS',T"\!35/A:<1M-Z;!)DGH-1
M 6V @1P-5*O@7W;W!KW!8 #@'=2BD$MKR.ZF58+[Y6C#K/JMTM8;]YFA"!^0
M6R%UB@;.6 KY@Y]A^X2Z/WSZ#&W4M((IZ[$=:&):96QN21_3RBKG53_=IPEPU'#$ATG*4!+ @#"Y"=!B
MI@!O,.)QF/9AZ'[HA\!@P'[[Z*$?DCYZ@-E#[_2><<$TT1@E@S 3#!S&$ORY
MX26V$&?I*,K$@!B12"PH5&"<)[R)KJ 5AZ8"IRFB